Aqueous formulation comprising paracetamol and ibuprofen

ABSTRACT

An aqueous ibuprofen and paracetamol composition has a pH 6.3-7.3. The composition can be used as a medicament, especially for the treatment of pain and/or inflammation. The composition can be formulated for intravenous injection.

INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS

Any and all applications for which priority claims are identified in theapplication data sheet, or any correction thereto, are herebyincorporated by reference, including the claim that this application isa divisional of U.S. application Ser. No. 15/326,958, filed Jan. 17,2017, which is the U.S. National Phase of International Application No.PCT/EP2015/066466, filed Jul. 17, 2015, designating the U.S. andpublished in English as WO 2016/009067 on Jan. 21, 2016, which claimsthe benefit of International Application No. PCT/EP2014/065544, filedJul. 18, 2014 and published in English as WO 2016/008546 on Jan. 21,2016.

BACKGROUND OF THE INVENTION Field of the Invention

The present invention relates to a method for the preparation of astable aqueous formulation combining ibuprofen and paracetamol, tocompositions obtained using the method, and to their use as a medicineespecially for intravenous injection or infusion.

The invention is particularly useful for use in hospitals where it isdesirable to have access to stable liquid pharmaceutical formulationscombining ibuprofen with paracetamol for administration by injection, inparticular for intravenous injection or infusion.

Description of the Related Art

Ibuprofen is a known non-steroidal anti-inflammatory drug that possessesanalgesic and antipyretic activities. Its chemical name is2-(p-isobutylphenyl)propionic acid. It is indicated in the treatment forrelief of signs and symptoms of rheumatoid arthritis and osteoarthritis,mild to moderate pain and treatment of primary dysmenorrhea.

Ibuprofen is very poorly soluble in water. Consequently dosage formssuch as oral or injectable liquids have been difficult to develop. Anapproach followed to improve water solubility has been the use ofwater-soluble complexes and the preparation of an ibuprofen salt such assodium or with an amino acid.

Paracetamol, also known as acetaminophen, is a known non-opiate,non-salicylate analgesic and antipyretic drug. Its chemical name isN-(4-hydroxyphenyl)acetamide. It provides temporary relief of minoraches and pains with heartburn or acid ingestion and upset stomachassociated with these symptoms.

It is known that paracetamol in aqueous solution is liable to undergohydrolysis. The formation of p-aminophenol following hydrolysis ofparacetamol which itself can degrade into quinoneimine is for instancedescribed in the publication of J. E. Fairbrother, “Acetaminophen” inAnalytical Profiles of Drug Substances, 1974, vol. 3, pages 1-109. Therate of degradation of paracetamol increases with increasing temperatureand light. This rate is minimal at a pH in the region of 6 (K. T. Koshyet al., 1961, J. Pharm. Sci. 50, pages 116-118). Paracetamol is alsoknown as being susceptible to oxidation. Its stability in aqueoussolutions therefor requires the use of antioxidants and/or the removalof oxygen from the solution. This poses extra constrains on thedevelopment of a formulation for intravenous injection on account of thetoxicity of some antioxidants and/or complexity to remove oxygen whichdissolves easily in water. Depending on the technique used the removalof oxygen may require a considerable amount of time. Anotherdisadvantage is that oxidation products lead to the formation ofcoloured compounds, making the aqueous solution unsuitable fortherapeutic applications.

Use of ibuprofen alone is associated with a number of side effects suchas rash, ringing in the ears, headaches, dizziness, drowsiness,abdominal pain, nausea, diarrhoea, constipation and heartburn. The sideeffects may lead to patient discomfort and may result in poor medicationfollow up. A known approach is the combination with other activeprinciples complementary to ibuprofen, preferably allowing a lower doseof ibuprofen.

There is a demand in the field for products that combine ibuprofen andparacetamol, especially in a form suitable for intravenous injection.

The pH of existing formulations in the market of ibuprofen alone isabout 7. Ibuprofen sodium formulations commonly have a pH ranging from7.0 to 7.4 and are buffered. Ibuprofen lysate formulations have a pHranging from 6.8 to 7.1. The pH of existing paracetamol formulations inthe market is about 5.5 to 6.0. The pH of 7 avoids precipitation ofibuprofen and the pH of 5.5 to 6.0 is advantageous for paracetamol ashydrolytic degradation of paracetamol is minimal at this pH. At pH 7degradation of paracetamol is significant and at pH 5.5 to 6.0 ibuprofenprecipitates.

It is the aim of the present invention to provide a combination productof ibuprofen and paracetamol that solves at least one of the problemsdescribed above. In particular the invention aims to provide acombination product in aqueous form suitable for intravenous injection.It is a further object of the invention to provide a method for thepreparation of the ibuprofen/paracetamol combination.

SUMMARY OF THE INVENTION

The current invention provides a solution for at least one of the abovementioned problems by providing a composition combining ibuprofen andparacetamol with improved compatibility.

In a first aspect, the present invention provides in a process formanufacturing an aqueous composition comprising ibuprofen andparacetamol in combination, comprising the steps of:

-   -   a) providing an aqueous solvent of pH 6.0-8.0, preferably        6.2-7.5, more preferably 6.3-7.3,    -   b) dissolving in said aqueous solvent ibuprofen and paracetamol,    -   c) if required adjusting the pH to 6.3-7.3,    -   d) thereby obtaining said aqueous composition comprising        ibuprofen and paracetamol in combination at pH 6.3-7.3.

More specifically, a process for manufacturing an aqueous compositioncomprising ibuprofen and paracetamol in combination, comprising in orderthe steps of: providing an aqueous solvent of pH 6.0-8.0, preferably6.2-7.5, more preferably 6.3-7.3, and dissolving in said aqueous solvent2.8 to 3.2 mg ibuprofen and 9.8 to 10.2 mg paracetamol expressed per mlof said composition. The pH of the final composition obtained should bebetween pH 6.3-7.3. Thus, if required, the pH is adjusted.

This method has the advantages that conditions are used which at thesame time overcome poor ibuprofen solubility and paracetamol sensitivityto degradation. The resulting product has long term storage stability.

In a second aspect, the present invention provides aqueous compositions,preferably obtained by a method of the invention.

More specifically, the invention provides an aqueous composition,comprising ibuprofen and paracetamol, wherein the pH of said compositionis 6.3 to 7.3.

Products according to an embodiment of the invention are characterizedin that they provide a stable combination of ibuprofen and paracetamolat a physiologically acceptable pH.

In a third aspect, the present invention provides medical uses of thecompositions according to the invention. Products according to theinvention can be advantageously used to administer at the same timeibuprofen and paracetamol. The problem of managing the two drugsseparately is overcome.

In a forth aspect, the invention provides in an device for delivery ofan aqueous solution of ibuprofen and paracetamol at pH 6.3-7.3 inaccordance with the invention.

The invention thereto provides a device (1) comprising a compositionaccording to an embodiment of the invention for delivering said aqueouscomposition by means of injection or infusion. This device can be asyringe or infusion bag.

This device can be ready for use. i.e. comprising said aqueous solutionof ibuprofen and paracetamol at pH 6.3-7.3. It can also be equipped formixing of separate components of the solution prior to administration.

In a preferred embodiment said device comprises

-   -   at least a first and a second reservoir (2,3), wherein ibuprofen        is comprised in a first reservoir (2) and paracetamol is        comprised in a second reservoir (3), and    -   a mixing zone (9) for combining said paracetamol and said        ibuprofen prior to delivery,

characterized in that, said combination is a composition according to anembodiment of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts several different embodiments a-c of an infusion bag 1,as examples of delivery devices according to the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Unless otherwise defined, all terms used in disclosing the invention,including technical and scientific terms, have the meaning as commonlyunderstood by one of ordinary skill in the art to which this inventionbelongs. By means of further guidance, term definitions are included tobetter appreciate the teaching of the present invention.

As used herein, the following terms have the following meanings:

“A”. “an”, and “the” as used herein refers to both singular and pluralreferents unless the context clearly dictates otherwise. By way ofexample, “a compartment” refers to one or more than one compartment.

“About” as used herein referring to a measurable value such as aparameter, an amount, a temporal duration, and the like, is meant toencompass variations of +/−20% or less, preferably +/−10% or less, morepreferably +/−5% or less, even more preferably +/−1% or less, and stillmore preferably +/−0.1% or less of and from the specified value, in sofar such variations are appropriate to perform in the disclosedinvention. However, it is to be understood that the value to which themodifier “about” refers is itself also specifically disclosed.

“Comprise,” “comprising,” and “comprises” and “comprised of” as usedherein are synonymous with “include”, “including”, “includes” or“contain”, “containing”, “contains” and are inclusive or open-endedterms that specifies the presence of what follows e.g. component and donot exclude or preclude the presence of additional, non-recitedcomponents, features, element, members, steps, known in the art ordisclosed therein.

The recitation of numerical ranges by endpoints includes all numbers andfractions subsumed within that range, as well as the recited endpoints.All percentages are to be understood as percentage by weight and areabbreviated as “% wt”, unless otherwise defined or unless a differentmeaning is obvious to the person skilled in the art from its use and inthe context wherein it is used.

In a first aspect, the present invention provides in a process formanufacturing an aqueous composition comprising ibuprofen andparacetamol in combination, comprising the steps of:

-   -   a) providing an aqueous solvent of pH 6.0-8.0, preferably        6.3-7.3,    -   b) dissolving in said aqueous solvent ibuprofen and paracetamol,    -   C) if required adjusting the pH to 6.3-7.3,    -   d) thereby obtaining said aqueous composition comprising        ibuprofen and paracetamol in combination and pH 6.3-7.3.

More specifically, a method for the production of an aqueous compositioncomprising ibuprofen and paracetamol in combination according to anembodiment of the invention, comprises in prescribed order the steps of:providing an aqueous solvent of pH 6.0-8.0, preferably pH 6.3-7.3, anddissolving in said aqueous solvent 2.8 to 3.2 mg ibuprofen and 9.8 to10.2 mg paracetamol expressed per ml of said composition.

The invention also relates to a liquid formulation obtainable by amethod of the invention. The invention also relates to a liquidformulation obtained by a method of the invention.

With the term “aqueous” is meant, comprising water. Preferably theaqueous solvent is water and more preferably a saline solution.

Preferably, the ibuprofen and paracetamol are dissolved in the aqueoussolvent under mechanical agitation e.g. stirring. Ibuprofen ispreferably used in the form of ibuprofen sodium. The amount of ibuprofenin the combination product is 2.8 to 3.2 mg per ml of the composition;preferably the amount is 3.0 mg/ml. Preferably ibuprofen sodium is used.For an amount of 3.0 mg ibuprofen/ml 3.85 mg ibuprofen sodium is used.

The amount of paracetamol in the combination product is 9.8 to 10.2 mg;preferably 10.0 mg/ml.

The aqueous solvent to which the active ingredients are added ischaracterized by a pH of 6.0-8.0, preferably 6.2-7.5, preferably 6.3 to7.3. In a more preferred embodiment, the aqueous solvent has a pH of6.4-6.6. In a more preferred embodiment, the final composition has a pHof 6.4-6.6. With “final composition”, the composition is meant that willbe filled into receptacles and is stored. It was found advantageous tostart at the low end of the pH range. The final product has a pH onstorage that remains stable or may evolve within the specified range(6.3-7.3).

The pH range at the same time avoids the precipitation of ibuprofen anddegradation of paracetamol.

The pH may be adjusted to a desired level prior to admixing using a pHadjuster such as NaOH or HCl.

The pH of the solution may be buffered. Suitable buffering agents mayinclude one or more of citric acid, sodium citrate, sodium phosphate,potassium citrate, and the like. Preferably the buffering agent isdisodium phosphate.

In a preferred embodiment the aqueous solvent has a dissolved oxygencontent below 2 ppm.

An oxygen content of maximum 2 ppm is a favourable level for avoidingdegradation of paracetamol in the presence of ibuprofen, in the presentmethod and compositions obtained thereof.

In a preferred embodiment the oxygen content of the aqueous solution isbelow 5 ppm, preferably below 2 ppm, more preferably below 1 ppm, evenmore preferably below 0.5 ppm, most preferably below 0.2 ppm.

The dissolved oxygen content can be measured by techniques known to askilled person. The initial or residual dissolved oxygen content can bemeasured with the aid of an oxygen meter operating according to theClark principle giving the value of the oxygen content in mg/l. Thescale is calibrated between a point zero (reducing solution) and thecontent at oxygen saturation of distilled water, taking into account thetemperature of the medium and the atmospheric pressure. The oxygencontent is calculated using a chart as a function of the temperature andthe pressure.

In a preferred embodiment of a process of the invention the reduceddissolved oxygen content is obtained using an aqueous solvent having atemperature, as from the outset, of between 65° C. and 99° C.,preferably between 80° C. and 98° C. In an embodiment, the inventionrelates to a method as defined herein, wherein the aqueous solvent has,as from the outset, a temperature between 85° C. and 97° C. or between90° C. and 95° C.

A preferred process comprises admixing of the active principles to theaqueous solvent that has a raised temperature. Advantageously, theaqueous solvent is not cooled prior to admixture of the activeprinciple, which constitutes not only a gain in the preparation time ofthe formulation as there is no need to use heat exchangers to cool theaqueous solvent, but also permits to obtain a suitable oxygenconcentration. Addition of the oxygen sensitive paracetamol andanti-oxidant to a medium with lowered oxygen content, as opposed todeoxygenation of the solution already containing these ingredients, hasthe advantage that the detrimental effects of oxygen are kept minimal.The anti-oxidant is not prematurely consumed as remains available toprovide long term storage stability.

In another preferred embodiment of a process of the invention thereduced oxygen content is obtained by bubbling of an inert gas throughsaid solvent. The gas that is bubbled into the solution to drive outoxygen may be nitrogen, argon or xenon. Preferred is nitrogen. Mostpreferred is nitrogen with low oxygen content.

In another embodiment of a process of the invention the reduced oxygencontent is obtained using vacuum. Vacuum may be obtained using anappropriate vacuum pump such as a vane pump.

Techniques for reduction of the oxygen content in the formulation, suchas the warm water, bubbling and/or vacuum method as described above, maybe combined.

In a preferred embodiment, the solution before filling in a receptacle,is topped up with an inert gas, such as nitrogen, argon or xenon.Preferred is argon. The use of argon is advantageous as it is heavierthan air and is believed to provide a protective layer on top of thesolution.

In a preferred embodiment of a process of the invention, the pH of theaqueous solvent in step a) is 6.3 to 6.5. Starting the process at a pHof 6.4±0.1 has the advantage that the resulting composition has a longerstorage stability.

In a preferred embodiment, solutions prepared with a process of theinvention, with pH of 6.4+/−0.1, have a storage stability of at least 6months, preferably 12 months, more preferably 18 months, most preferably18 months.

In another preferred embodiment, solutions prepared with a process ofthe invention, with pH of 6.3-6.6 at the time of preparation (t₀), havea storage stability of at least 6 months (t₆), preferably at least 8months (t₈), more preferably at least 10 months (t₁₀), most preferablyat least 12 months (t₁₂).

In a preferred embodiment of a process and composition of the invention,an anti-oxidant is added to the aqueous composition. Anti-oxidants foruse in the invention are preferably selected from the list of asulphite, or sulphite derivative, a thiolic substance such as, forexample, cysteine, acetylcysteine, dithiothreitol or alpha-thioglycerol,thiomalic acid, thioglycerol, methionine; a hydroxylated substance suchas ascorbic acid, iso-ascorbic acid, mannitol, sorbitol, anethylenically unsaturated substance such as sorbic acid, undecylenicacid or fumaric acid or a hydroxy polycarboxylic acid, or a reducingsugar such as trehalulose, maltulose or isomaltulose. In a preferredembodiment the anti-oxidant is selected from a cysteine and acetylcysteine. Cysteine is preferably cysteine hydrochloride. The acetylcysteine or cysteine hydrochloride is preferably the monohydrate. By theterm “(acetyl)cysteine” as used herein, is meant acetylcysteine and/orcysteine. Acetyl cysteine or cysteine as anti-oxidant suppresses thegeneration of unknown degradation products of paracetamol by oxidation.In spite of the risk that their use will provide yellow solutions, theyare preferred as they can reduce the risk of paracetamol toxicity.

In case the warm water technique is used, the temperature of thecomposition is lowered to 40° C. or lower prior to addition of cysteineor acetyl cysteine. The cooling may be under mechanical agitation e.g.stirring. The anti-oxidant is added at a temperature of at most 40° C.to avoid degradation of the acetyl cysteine or cysteine at highertemperatures. The aqueous solution comprising ibuprofen and paracetamolis then cooled to a temperature of at most 40° C., preferably to 39° C.or 38° C., 37° C., 36° C. or 35° C., prior to the addition of acetylcysteine or cysteine. Preferably the addition of cysteine or acetylcysteine to said aqueous solvent does not change said pH outside of 6.3and 7.3. In a preferred embodiment, the aqueous composition has a pH of6.3 to 7.3 prior to and after addition of the anti-oxidant. Preferablythe pH of the final product is around 6.6.

In a preferred embodiment of a process and composition of the inventionthe aqueous solvent further comprises an isotonic agent. Use of anisotonic agent has the advantage that an osmotic pressure is created inthe region of that of physiological saline. The isotonic agent hereinmay be a polyol, a sugar, a linear or cyclic glucitol having from 2 to10 carbon atoms selected from mannitol, sorbitol, inositol, glucose andglycerol. A preferred isotonic agent is mannitol.

The mass ratio (w/w) of the isotonic agent to paracetamol, for instancemannitol:paracetamol, is preferably 2 to 6:1, more preferably 3 to 5:1,most preferably around 4:1. Preferably the isotonic agent is added tothe aqueous solution, preferably water, prior to the addition ofibuprofen and paracetamol.

In a preferred embodiment, the pH adjusters used in a method accordingto the invention, are sodium hydroxide-disodium phosphate salt andacetyl cysteine or cysteine.

In a preferred embodiment the final pH of the formulation is from 6.3 to7.3. Preferably the final pH is 6.4 to 6.9, more preferably 6.5 to 6.8.In a preferred embodiment of a process of the invention the aqueouscomposition obtained has a pH around 6.6. Preferably the pH is 6.3 to7.3 after a shelf-life of at least six months.

After the additions are complete, the reaction vessel is closed, and theair remaining in the upper side of the vessel is compressed by an inertgas such nitrogen, introduced from the upper side of the vessel.Preferably the pressure is at 1-1.5 bar. Following the introduction ofinert gas, stirring ensues.

Preferably, the mass ratio (w/w) of cysteine hydrochloride toparacetamol is 0.010 to 0.040:1, preferably 0.020 to 0.030:1, preferably0.025:1.

Preferably, the mass ratio (w/w) of acetyl cysteine or cysteinehydrochloride to ibuprofen is 0.20 to 0.40:1, preferably 0.10 to 0.20:1,preferably 0.08:1.

For example, in a formulation and method as defined herein,(acetyl)cysteine hydrochloride may be present in the final formulationin an amount preferably between 0.015% and 0.05%, preferably around0.025% (w/v).

The solution obtained may be filtered, for example in a filtration unit.

As during compounding, oxygen contact or oxygen ingress into the aqueoussolution during filling/packaging and/or storage is preferably avoided.

Preferably the containers, such as vials, for receipt of theparacetamol-ibuprofen solution are washed with warm water prior tofilling. In particular, the containers may be washed with water forinjection at a temperature of 75° C.-100° C. This water has a lowdissolved oxygen content. It is particularly suitable to take up oxygenfrom the container and reduced its oxygen content.

In a subsequent step, the washed containers may be dried. Preferablydrying is carried out with dry air. Dry air with low moisture content,again minimizes re-uptake of oxygen by the packaging and later on by theparacetamol-ibuprofen solution.

After drying the washed and/or dried containers may be rinsed withnitrogen. Preferably nitrogen low in oxygen is used.

Following the pre-treatment of the containers, said containers arefilled with the ibuprofen/paracetamol solution.

The compounding procedure preferably provides an aqueousibuprofen/paracetamol solution prior to filling/packaging with adissolved oxygen content of below 2.0 ppm, more preferably below 1.0ppm, even more preferably below 0.8 ppm, most preferably below 0.5 ppm;typically around 0.4 ppm.

In a preferred embodiment, a paracetamol-ibuprofen solution preparedaccording to a method of the invention has less than or equal to 0.8 ppmdissolved oxygen during filing.

Preferably the containers are sealed under vacuum; preferably saidvacuum is between 450 mbar and around 1 bar.

The containers are then sealed, for instance by adding a stopper,sealing under vacuum and providing a crimping cap covering the stopper.

These bottles can subsequently be heat-sterilised, for instance for 15minutes at 121° C.

In a preferred embodiment, a method according to the invention furthercomprises in specified order the steps of:

-   -   ashing said containers with water for injection at a temperature        of 75° C.-100° C.,    -   drying said washed containers with dried air.    -   rinsing said washed containers with nitrogen.    -   filling said nitrogen washed container with the        ibuprofen/paracetamol aqueous solution.    -   sealing said container under vacuum, preferably between 450 mbar        and around 1 bar.

In a more preferred embodiment, said vacuum sealed product containercomprises a stopper made of an elastic material covered by a crimpingcap.

In a preferred embodiment said elastic material of the stopper isrubber, preferably a butyl rubber or halo butyl rubber. These rubbertypes have a low oxygen transmission coefficient. Preferably the stopperis sealed by an aluminium crimping caps. Preferably said vial is closedwith a (halo)butyl rubber stopper, preferably bromobutyl rubber, andsealed by an aluminium caps.

Preferably the container used to obtain a product according to anembodiment of the invention is a vial; preferably a colourless type IIglass Eur. Ph. 3.2.1 vial.

In a preferred embodiment according to the invention the closed productcontainer has reduced pressure inside. Preferably the pressure isreduced to allow the addition of solvent for injection to the closedsystem, e.g. by means of penetrating the closure with a needle.Preferably the reduced pressure is between 450 mbar and around 1 bar.

In a preferred embodiment the container comprises a vial with a blowback inside of the flange. The blow back improves the fit of the stopperand avoids that the stopper pops out of the vial. The flange of the vialand the dimensions of the stopper are chosen in a way to guarantee agood fit of the stopper during stoppering and sealing. It is preferredto have a blow back with dimensions in size to provide sufficientsealing surface between the vial and the stopper in order to keep avacuum in the vial as long as possible.

Preferably the container/closure system has a blow back; particularlywhen applying reduced pressure. In comparison to systems having no blowback, blow back systems are very tight and the risk of influx of air andthus oxidation can be reduced.

A formulation according to an embodiment of the invention can generallybe prepared as follows. First, exact quantities of the formulation ofisotonic agent (mannitol), ibuprofen sodium and hydrochloric acid in anamount to obtain a pH of 6.3-7.3 are added to a reaction vessel.Optionally one or more other water-miscible solvent(s), and/orsurfactants may be present. Then, as solvent, water for injections isprovided at a temperature of between 65° C. and 98° C. The reactionvessel is closed and the air remaining in the upper side of the vesselis compressed by 0.22 μm filtered nitrogen introduction from the upperside of the vessel. Then components are dissolved by stirring. Afterstirring is stopped the reaction vessel is quickly opened andparacetamol is quickly added. The procedure is at this point carried outwithout mixing to reduce the introduction of air. Then the reactionvessel is closed. Air is hardly soluble in water when it is at atemperature of more than 60° C.

Remaining air in the upper side of the vessel is compressed by 0.22 μmfiltered nitrogen from the upper side, preferably at 1-1.5 bar, thenstirring ensues. The solution is cooled to a temperature of at most 40°C. Once cooled, reaction vessel is quickly opened and exact quantitiesof sodium hydroxide and disodium phosphate of the formulation, forobtaining a pH 6.3-7.3, are quickly added and reaction vessel is closed.Remaining air in the upper side of the vessel is compressed by 0.22 μmfiltered nitrogen from the upper side, preferably at 1-1.5 bar, stirringensues. The reaction vessel is quickly opened and cysteine or acetylcysteine is quickly added and the reaction vessel is again closed. Theair remaining in the upper side of the vessel is compressed by 0.22 μmfiltered nitrogen introduced from the upper side, preferably at 1-1.5bar, then stirring ensues. The nitrogen used is filtered prior to itsintroduction with a 0.22 μm filter.

In a second aspect the present invention provides an aqueouscomposition, comprising ibuprofen and paracetamol, wherein the pH ofsaid composition is 6.3 to 7.3.

More specifically, an aqueous composition comprising 2.8 to 3.2 mgibuprofen, 9.8 to 10.2 mg paracetamol and cysteine expressed per ml ofsaid composition, preferably prepared according to the method previouslydescribed, characterized in that, the pH of said composition is 6.3 to7.3.

The present inventor has found that the indicated pH range unexpectedlyallows the combination of ibuprofen and paracetamol in aqueous solutionthereby at the same time reducing ibuprofen precipitation andparacetamol degradation.

Preferably the aqueous solvent comprises water and an isotonic agent. Ina more preferred embodiment said isotonic agent is mannitol.

More pharmaceutically acceptable excipients may be present. However, ina preferred embodiment there are no additional excipients present.

Preferably the aqueous solution has an osmolality of between 285-320mOsmol/l as determined by point depression according to USP 788.

In a preferred embodiment said composition has a storage stability of atleast 6 months, preferably at least 9 months, more preferably at least12 months, most preferably 24 months, based on the paracetamol/ibuprofencontent as measured by HPLC in accordance with European Pharmacopeia2.2.29 and USP 621.

In a preferred embodiment, the (acetyl)cysteine amount in thecomposition at the completion of its preparation is at least 80%,preferably at least 85%, most preferably at least 90%, of the initialamount added.

In a preferred embodiment, the (acetyl)cysteine hydrochloride content isat least 40% of the initial amount added, preferably at least 50%,preferably at least 75%, during the shelf-life of theibuprofen/paracetamol solution. A low consumption of (acetyl)cysteine isindicative of a low exposure to oxygen during the period of storage.

In a further embodiment said composition is for use as a medicament.Especially important for its suitability in the pharmaceutical andmedical field is the pH of the composition.

In a more preferred embodiment said composition is for use in thetreatment of pain and/or of inflammation.

Its pH makes the composition particularly suitable for administration byintravenous injection. In a most preferred embodiment said compositionis for administration by intravenous injection.

The solutions thus obtained may be distributed into ready-to-usehermetically stoppered or sealed, bags, pouches or bottles.

In a third aspect the invention provides in a device comprising acomposition according to an embodiment of the invention for deliveringsaid aqueous composition by means of injection or infusion.

In a preferred embodiment, said device comprises

-   -   at least a first and a second reservoir, wherein ibuprofen is        comprised in a first reservoir and paracetamol is comprised in a        second reservoir, and    -   a mixing zone for combining said paracetamol and said ibuprofen        prior to delivery,

characterized in that, said combination is a composition according to anembodiment of the invention.

In a preferred embodiment, said first and second reservoir are separatedfrom each other by temporary separation means. Upon connection of thereservoirs by removal or opening of the separation means, the reservoirsare used as a mixing zone.

This has the advantage that the different components can be formulatedin the for each component most stable storage conditions. This allowsstoring the amount of paracetamol separately at its most favourable pHfrom the amount of ibuprofen at its most favourable pH. Alternatively,it allows storage of the aqueous solvent separately from the amount ofparacetamol or ibuprofen. Just before administration of the compositionto a patient, the temporary sealing means are removed or opened and thedifferent components can be mixed together.

The term “device” refers to a medical device for parenteraladministration of a composition, preferably intravenous administrationof a liquid composition.

In a preferred embodiment, the injection device is in the form of asyringe.

This has the advantage that a medical practitioner knows how to use saidinjection device.

In a preferred embodiment, the injection device is in the form of aninfusion bag.

This has the advantage that larger volumes can be administered to thepatient, and hence larger quantities of ibuprofen and paracetamol can beadministered than with a syringe. The speed of administration can becontrolled so that administration over a long period of time can beachieved.

The term “temporary sealing means” refers to means to prevent a fluid toflow from one reservoir to another, or to prevent a fluid to flow from areservoir to the mixing zone. These means can be broken, opened orremoved in a way fluid can flow from said reservoirs. The sealing meanscan be broken, opened or removed reversibly or permanently. The sealingmeans can be a tap, a valve, a breakable protrusion or a weakenedsection in the separation between the reservoirs or mixing zone.

In a preferred embodiment, the aqueous solvent is divided over thedifferent reservoirs and can have a different pH in each reservoir.

In a preferred embodiment, the pH of solutions in the said at least tworeservoirs is different, preferably 1.0 to 2.0 pH units difference. Thiscorresponds for instance, to a paracetamol solution with pH 5.8-6.0 inone reservoir, and an ibuprofen solution of pH 7.0-8.0 in anotherreservoir.

This has the advantage that one reservoir can hold ibuprofen at its moststable pH and another reservoir can hold paracetamol at its most stablepH.

In a preferred embodiment, the injection device is comprising in a firstreservoir said ibuprofen solubilised in water at pH 7.0-8.0.

This has the advantage that ibuprofen is already solubilized so thatupon administration no time needs to be spend solubilizing the amount ofibuprofen. The pH at which the ibuprofen is solubilized is the pH atwhich an ibuprofen solution is most stable, meaning the smallest amountof decomposition of ibuprofen occurs. This allows the ibuprofen solutionto be stored preferably at least one year, more preferably at least 2years.

In a preferred embodiment, the injection device is comprising in asecond reservoir said paracetamol solubilised in aqueous solvent of pHof 5.5 to 6.0.

This has the advantage that paracetamol is already solubilized so thatupon administration no time needs to be spend solubilizing the amount ofparacetamol. The pH at which the paracetamol is solubilized is the pH atwhich a paracetamol solution is most stable, meaning the smallest amountof decomposition of paracetamol occurs. This allows the paracetamolsolution to be stored preferably at least six months, more preferablyone year, most preferably at least 2 years.

In a preferred embodiment, the injection device comprises a mixing zone,temporarily or permanently, fluidly separated from said reservoirs. Themixing zone is preferably fluidly separated from said reservoirs bytemporary scaling means.

This has the advantage that only in the mixing zone conditions areunfavourable for long term storage. The composition will only be presentin the mixing zone for a short time before administration. This time istoo short to for one of the components of the composition to decompose.

In a more preferred embodiment, one of the reservoirs or both of thereservoirs become the mixing zone after the removal of the temporarysealing means.

This has the advantage that no empty volumes need to be provided. Theempty volumes have the disadvantage that these can be filled with air,and precaution needs to be taken that the air does not get into thebloodstream upon administration.

The pH in the mixing zone is 6.3 to 7.3. It has been shown by theinventor that this is the optimal pH range for having both ibuprofen andparacetamol in solution in terms of stability.

In a preferred embodiment, a device is foreseen with an injection meansand the injection means is a hypodermic needle or a connector to ahypodermic needle, a catheter or a drip.

This has the advantage that the injection device can be integrated incommon medical practice.

In a further aspect of the invention, the composition is provided in adouble chambered device, preferably an injection device.

In a preferred embodiment said injection device is provided with acomposition according to an embodiment of the invention. Preferably itis comprising a first and a second reservoir, wherein ibuprofen in anamount for providing 2.8 to 3.2 mg ibuprofen expressed per ml of saidcomposition is comprised in one of the reservoirs and paracetamol inamount for providing 9.8 to 10.2 mg paracetamol expressed per ml of saidcomposition is comprised in the other reservoir, characterized in that,the pH of said composition when the content of both reservoirs is mixedis from 6.3 to 7.3.

In a preferred embodiment said injection device is provided with acomposition according to an embodiment of the invention comprising afirst and a second reservoir, wherein 2.8 to 3.2 mg ibuprofen expressedper ml of said composition is comprised in one of the reservoirs and 9.8to 10.2 mg paracetamol expressed per ml of said composition is comprisedin the other reservoir, characterized in that, the pH of saidcomposition when the content of both reservoirs is mixed is from 6.3 to7.3.

In a preferred embodiment the injection device, comprises a first and asecond reservoir, which first reservoir has a first open end throughwhich the second reservoir can be mounted sliding in the firstreservoir, which first reservoir has a second end located opposite thefirst end and on which an injection needle can be arranged, which secondreservoir comprises a base surface which is fitted with an outlet,wherein at the outlet is arranged a protrusion which in mounted state ofthe injection device extends from the base surface in the direction ofthe second end, which protrusion is arranged breakably on the basesurface of the second reservoir, such that when the protrusion reachesthe second end it breaks away to open the outlet of the secondreservoir.

Such an injection device is characterised in that a protrusion ismounted at the outlet and in the mounted state of the injection deviceextends from the base surface towards the second end, which protrusionis mounted breakably on the base surface of second reservoir, such thatwhen the protrusion reaches the second end, it breaks off to open theoutlet of the second reservoir. Because the protrusion is arranged onthe base surface of the second reservoir and breaks away on reaching thesecond end, it does not form an obstacle for the outflow of themedication from the first reservoir. The evacuation of the firstreservoir is therefore optimal. Because in addition the protrusion isarranged at the outlet of the second reservoir in the base surface, thiscan take place at the same time as the production of the injectiondevice without extra steps on injection moulding of the secondreservoir. The injection device is cheap to produce.

Suitable devices, in particular syringes, for use in the presentinvention are for instance described in BE1020614.

The invention is described in greater detail in the examples below,which are given as non-limiting illustrations. In these examples, thetemperature is room temperature or is expressed in degrees Celsius, andthe pressure is atmospheric pressure. The water and all the reagentsused are of injectable grade.

Moreover, all the examples form an integral part of the invention, asdoes any characteristic of the description including the examples, whichappears to be novel with respect to any prior art, in the form of ageneral characteristic rather than of a particular characteristic of theexample.

EXAMPLES

In the following, examples are intended to further clarify the presentinvention, and are nowhere intended to limit the scope of the presentinvention.

1. Preparation of Liquid Pharmaceutical Formulations According to thePresent Invention

Formulations were prepared by admixing isotonic agent (mannitol)ibuprofen, hydrochloric acid, water for injections, paracetamol andacetyl cysteine or cysteine, and pH is at 6.3-7.3 by hydrochloric acid,sodium hydroxide and disodium phosphate. The preparation of thecomposition was followed by filtration and filling of glass vials orbottles. The filtration of the solution took place at a temperaturebelow 40° C. These receptacles were sterilized for 15 minutes at 121° C.

The relevant manufacturing steps are performed quickly and without anyunnecessary interruption in order to avoid incorporation of air in thecompounding vessel and to keep the solution at the required temperaturesi.e. between 65° C. and 98° C. for the admixing steps before acetylcysteine or cysteine are added; and below 40° C. for the acetyl cysteineor cysteine addition part.

The air inside the reaction vessel was compressed from the upper side ofthe vessel by 0.22 μm filtered nitrogen pressure. The nitrogen pressureapplied on the solution in the compounding vessel pushes the solutionthrough the filter.

Finally, the filled vials were sterilized at 121° C. for 15 minutes.

TABLE 1 Formulation 1 Unit formula Name of ingredient 100 ml Formula per1 ml Ibuprofen sodium Equivalent to 300 mg Equivalent to 3 mg ibuprofenibuprofen Paracetamol 1.0 g 10 mg Mannitol 3.2850 g 32.850 mgHydrochloric acid to pH = 6.6 to pH = 6.6 Cysteine hydrochloride 25.0 mg0.25 mg monohydrate Di sodium phosphate 13.0 mg 0.13 mg dihydrate Sodiumhydroxide to pH = 6.6 to pH = 6.6 Water For Injection q.s. ad 100.0 mlq.s. ad 1.0 ml Nitrogen Low Oxygen q.s. q.s.

2. Preparation of an Alternative Liquid Pharmaceutical FormulationAccording to the Present Invention

An alternative formulation was prepared according to the methoddescribed under Example 1.

TABLE 2 Formulation 2 Name of ingredient Unit formula 100 ml Formula per1 ml Ibuprofen sodium Equivalent to 300 mg Equivalent to 3 mg ibuprofenibuprofen Paracetamol 1.0 g 10 mg Mannitol 3.2850 g 32.850 mgHydrochloric acid 1M/ to pH = 6.4 to pH = 6.4 Sodium hydroxide 1MCysteine hydrochloride 25.0 mg 0.25 mg monohydrate Di sodium phosphate15.0 mg 0.15 mg dihydrate Water For Injection q.s. ad 100.0 ml q.s. ad1.0 ml Nitrogen Low Oxygen q.s. q.s.

3. Storage Stability Data

An ibuprofen/paracetamol combination product was prepared as follows:

To a mixing tank were added mannitol, ibuprofen, hydrochloric acid 0.1Nfor obtaining a pH of 6.3 to 7.3 and water for injections (WFI) at atemperature above 75° C. The quantity of hydrochloric acid to be addedwas calculated in advance and is such that the desired pH is maintained6.3-7.3. The mixing vessel was closed and the air remaining in the upperside of the vessel was compressed by 0.22 μm filtered nitrogenintroduced from the upper side, at 1-1.5 bar, followed by stirring.

The mixing vessel was quickly opened and paracetamol was quickly addedwithout stirring. The mixing vessel was closed and the remaining air inthe upper side of the vessel was compressed by 0.22 μm filtered nitrogenintroduced from the upper side of the vessel, at 1-1.5 bar, followed bystirring.

The solution was cooled to a temperature below 40° C. The temperaturereached, the mixing vessel was quickly opened and sodium hydroxide 0.1 Nand disodium phosphate were quickly added without stirring. Mixingvessel was closed and the air remaining in the upper side of the vesselwas compressed by 0.22 μm filtered nitrogen introduced from the upperside of the vessel, at 1-1.5 bar, followed by stirring.

The quantities of sodium hydroxide and disodium phosphate to be addedwere calculated in advance and are such that the desired pH ismaintained at 6.3-7.3 after the addition of cysteine.

The mixing vessel was quickly opened and acetyl cysteine or cysteine wasquickly added without stirring. The mixing vessel was closed and the airremaining in the upper side of the vessel was compressed by 0.22 μmfiltered nitrogen introduced from the upper side of the vessel, at 1-1.5bar, followed by stirring.

Samples were stored and analysed after set time-intervals. The resultsfor the solutions of pH 6.6 stored at a temperature of 25+/−2° C. at arelative humidity of 40+/−5% are summarized in Table 8. Those of pH 7.0stored at a temperature of 25+/−2° C. at a relative humidity of 40+/−5%are provided in Table 9. Further results from a storage stability teston samples prepared as previously described, are provided in Table 10.These samples were kept at a temperature of 25+/−2° C. and a relativehumidity of 40+/−5%. Those of pH 6.4 stored at a temperature of 25+/−2°C. at a relative humidity of 60+/−5% are provided in Table 11.

A series of analysis was performed on the sample. The appearance of asolution was determined by visual inspection according to USP 641, pHvalues were determined using potentiometry using USP 791, coloration wasdetermined following Eur. Ph 2.2.2 point depression USP 785, sub visibleparticles were assessed using a light obscuration particle count methodUSP 788, cysteine. HCl*H₂O, ibuprofen and acetaminophen were identifiedusing liquid chromatography USP 621. Acetaminophen content wasdetermined by HPLC, Eur. Ph. 2.2.29, 0049. Ibuprofen content and amountof cysteine HCl*H₂O are determined by liquid chromatography USP 621.Acetaminophen impurities were determined using Eur. Ph 2.2.29, 0049.Ibuprofen impurities were determined using Eur. Ph 2.2.29.

From the data in both tables it can be seen that a clear liquid solutionis provided. The physical appearance is obtained even after twelvemonths of storage and more. The cysteine content remains high andessentially stable over time. Impurity levels are very low for bothparacetamol and ibuprofen, in spite of the pH considered disadvantagesfor the active principles when present alone.

The storage stability test results indicate that a product shelf-life oftwo years is feasible. It can be concluded that the invention providesstable ibuprofen/paracetamol combination products of pH 6.3-7.3.

4. Compatibility

To test the compatibility of ibuprofen and paracetamol in combination,the following experiment was performed.

The pH 8.80 of a solution of 3.85 mg/ml of sodium ibuprofen 2H₂O,equivalent to 3 mg/ml of ibuprofen, in water is gradually decreased andthe absence or presence of precipitation is observed as an indication ofsolubility/compatibility. The results are noted down and summarized inTable 3. Precipitation of ibuprofen is observed once pH is at 5.75. TheIbuprofen solutions were stored for 1 month at 25° C. They were againobserved for signs of precipitation. The results are summarized in Table4. Ibuprofen solutions at pH 6 showed precipitation, whereas insolutions of ibuprofen at pH 6.2, precipitation was absent.

TABLE 3 Dissolution of sodium ibuprofen 2H₂O alone in water pH 3 4 5 5.55.8 6 6.2 6.4 6.6 6.8 7 7.5 Dissolved No No No No Yes Yes Yes Yes YesYes Yes Yes

TABLE 4 Dissolution of sodium ibuprofen 2H₂O in water after 1 monthstorage at 25° C. pH 5.8 6 6.2 6.4 6.6 6.8 7 7.5 Dissolution No No YesYes Yes Yes Yes Yes

In a further experiment the dissolution of sodium ibuprofen 2H₂O wasstudied in combination with paracetamol at a concentration of 10 mgparacetamol per liter. The results at varying pH are summarized in Table5. The results after one month of storage at 25° C. are provided inTable 6.

TABLE 5 Dissolution of sodium ibuprofen 2H₂O in the formulation 3 mg/mlParacetamol 10 mg/ml Ibuprofen pH 6.2 6.3 6.4 6.6 7 Dissolved Yes YesYes Yes Yes

TABLE 6 Dissolution of sodium ibuprofen 2H₂O in the formulationParacetamol-Ibuprofen-1 month pH 6.2 6.3 6.4 6.6 7 Dissolution No YesYes Yes Yes

TABLE 7 Dissolution of sodium ibuprofen 2H₂O in the formulationParacetamol-Ibuprofen-6 months, 25° C. pH 63 6.4 6.6 7 Dissolution YesYes Yes Yes

The amount of paracetamol was studied at varies points in time and fordifferent pH's. Data showed that minimal degradation of paracetamoloccurred at the pH range 6.3-7.3.

From the above it is concluded that the combination of ibuprofen andparacetamol is stable with a pH range of 6.3-7.3.

5. Injection Device

FIG. 1 depicts several different embodiments a-e, according to theinvention of injection devices in the form of an infusion bag 1. FIG. 1ashows in infusion bag 1 according to an embodiment of the inventioncomprising a first reservoir 2 holding an amount of ibuprofensolubilised 4 in a part of the aqueous solvent. The infusion bag alsocomprises a second reservoir 3 holding an amount of paracetamolsolubilised 5 in the rest of the aqueous solvent. The temporary sealingmeans 8 separate these reservoirs 2 and 3 from the mixing zone 9. Theinjection means 12 are connected to the mixing zone 9 and a flowregulator 11 is provided between said injection means 12 and said mixingzone 9. The infusion bag can be hung up by the fastening means 10. FIG.1b , shows an infusion bag 1 according to an embodiment of the inventionwith a similar setup but with reservoirs 2 and 3 having differentvolumes. FIG. 1c shows an infusion bag 1 with no separate mixing zone,the mixing zone is formed by reservoirs 2 and 3 once the temporarysealing means 8 are removed. FIG. 1d shows an infusion bag 1 with amixing zone 9 that is not housed in the infusion bag 1 itself. FIG. 1eshows an infusion bag 1 according to an embodiment of the invention.Reservoir 3 is holding an aqueous solvent 6 with a pH between 6.3 and7.3 and reservoir 2 is holding an amount of ibuprofen and an amount ofparacetamol 7 in dry conditions.

TABLE 8 storage stability date 3 mg/ml ibuprofen 10 mg/ml paracetamolwith cysteine (pH 6.6, 25 +/− 2° C., 40 +/− 5% relative humidity)Analysis Specification 1 month 2 months 3 months 6 months 9 months 12months 15 months 18 months 24 months Appearance of Clear liquid clearclear clear clear clear clear clear clear clear solution liquid liquidliquid liquid liquid liquid liquid liquid liquid pH value To bedetermined 6.66 6.66 6.69 6.70 6.75 6.72 6.79 6.81 6.83 Coloration ≤Y6<Y6 <Y6 <Y6 <Y6 <Y6 <Y6 <Y6 <Y6 <Y6 Sub visible particles ≥10 μm: 31581020 3885 905 2582 4895 N.R. 1790 888 ≤6000 p/vial ≥25 μm: 50 5 20 38 4765 N.R. 40 17  ≤600 p/vial Identification Cysteine HCl*H₂O Sameretention Complies Complies Complies Complies Complies Complies CompliesComplies Complies Ibuprofen time as standard Complies Complies CompliesComplies Complies Complies Complies Complies Complies AcetaminophenComplies Complies Complies Complies Complies Complies Complies CompliesComplies Acetaminophen 95-105%  104 104 104 101 99 101 103 104 103content (HPLC) Ibuprofen content 95-105%  104 104 103 102 103 100 102103 103 (HPLC) Cysteine HCl*H₂O Min 60%  89% 86% 87% 90% 87% 85% 90% 72%84% (HPLC) Impurities Acetaminophen Impurity K <0.05% 0.02 0.02 0.010.01 0.03 0.03 0.03 0.04 0.03 (4-aminophenol) Impurity F <0.05% 0.000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (4-nitrophenol) Any otherimpurity <0.10% 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.01 Totalimpurities  <0.2% 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 ImpuritiesIbuprofen Impurity A  <0.1% 0.0 0.0 0.0 0.0 0.0 0.0 0.00 0.00 0.00Impurity B  <0.2% 0.0 0.0 0.0 0.0 0.0 0.0 0.00 0.00 0.00 Any otherimpurity <0.10% 0.00 0.00 0.00 0.00 0.00 0.00 0.000 0.000 0.000 Totalimpurities  <0.2% 0.0 0.0 0.0 0.0 0.0 0.0 0.00 0.00 0.00

TABLE 9 storage stability data-3 mg/ml ibuprofen and 10 mg/mlparacetamol with cysteine (pH 7.0, 25 +/− 2° C., 40 +/− 5% relativehumidity) Analysis Specification Method and Method No. 1 month 2 months3 months 6 months Appearance of solution Clear liquid Visualinspection.USP<641> clear liquid clear liquid clear liquid clear liquidpH value To be determined Potentiometry.USP<791> 7.02 6.99 7.00 7.00Coloration ≤Y6 Eur.Ph 2.2.2 < Y6 < Y6 < Y6 < Y6 Sub visible particles≥10 μm: ≤6000 Light obscuration particle 3425 2810 1142 795 p/vial ≥25μm: ≤600 count method.USP<788> 37 10 3 5 p/vial Deliverable volumes >100ml Volume measurement. N.R. N.R. N.R. 103 USP<698> IdentificationCysteine HCl*H₂O Same retention time Liquid chromatography. CompliesComplies Complies Complies Ibuprofen as standard USP<621> CompliesComplies Complies Complies Acetaminophen Complies Complies CompliesComplies Acetaminophen content by HPLC 95-105%  Eur.Ph 2.2.29; 0049 9798 97 95 Ibuprofen content by HPLC 95-105%  Liquid chromatography. 99100 99 97.00 Cysteine HCl*H₂O by HPLC Min 60%  USP<621> 75% 72% 77% 83%Acetaminophen Impurity K (4-aminophenol) <0.05% Eur.Ph 2.2.29; 0049 0.020.02 0.02 0.03 Impurity F (4-nitrophenol) <0.05% 0.00 0.00 0.00 0.00 Anyother impurity <0.10% 0.01 0.01 0.01 0.01 Total impurities  <0.2% 0.20.2 0.1 0.2 Ibuprofen Impurity A  <0.1% Eur.Ph 2.2.29 0.0 0.0 0.0 0.0Impurity B  <0.2% 0.0 0.0 0.0 0.0 Any other impurity <0.10% 0.00 0.000.00 0.00 Total impurities  <0.2% 0.0 0.0 0.0 0.0

TABLE 10 storage stability test-3 mg/ml ibuprofen and 10 mg/mlparacetamol with cysteine (pH 6.6, 25 +/− 2° C., 40 +/− 5% relativehumidity) Analysis Specification Method and Method No. 1 month 2 months3 months 6 months Appearance of solution Clear liquid Visual inspection.USP<641> Complies Complies Complies Complies pH value To be determinedPotentiometry. USP<791> 6.96 6.95 7.02 7.00 Coloration ≤Y6 Eur.Ph 2.2.2<Y6 <Y6 <Y6 <Y6 Sub visible particles ≥10 μm: ≤6000 p/vial Lightobscuration particle 3250 1690 2992 2407 ≥25 μm: ≤600 p/vial  countmethod. USP<788> 33 0 3 15 Deliverable volumes >100 ml Volumemeasurement. USP<698> N.R. N.R. N.R. 102 Identification Cysteine HCl*H₂OSame retention time Liquid chromatography Complies Complies CompliesComplies Ibuprofen as standard USP<621> Complies Complies CompliesComplies Acetaminophen Complies Complies Complies Complies Acetaminophencontent by HPLC 95-105% Eur.Ph 2.2.29; 0049 103 103 103 100 Ibuprofencontent by HPLC 95-105% Liquid chromatography 104 104 104 102 CysteineHCl*H₂O by HPLC Min 60%  USP<621> 90 85 90 91 Acetaminophen Impurity K(4-aminophenol)  <0.05% Eur.Ph 2.2.29; 0049 0.02 0.02 0.02 0.02 ImpurityF (4-nitrophenol)  <0.05% 0.00 0.00 0.00 0.00 Any other impurity  <0.10%0.00 0.00 0.02 0.03 Total impurities  <0.2% 0.0 0.0 0.0 0.0 IbuprofenImpurity A  <0.1% Eur.Ph 2.2.29 0.0 0.0 0.0 0.0 Impurity B  <0.2% 0.00.0 0.0 0.0 Any other impurity  <0.10% 0.00 0.00 0.00 0.00 Totalimpurities  <0.2% 0.0 0.0 0.0 0.0

TABLE 11 storage stability test-3 mg/ml ibuprofen and 10 mg/mlparacetamol with cysteine (pH 6.4, 25+/− 2° C., 60 +/− 5% relativehumidity) Method and 1 3 6 9 12 Analysis Specification Method No.Release month months months months months Appearance of Clear liquidVisual inspection. clear clear clear clear clear clear solutionUSP<631>, liquid liquid liquid liquid liquid liquid Ph.Eur.2.2.1 pH6.3-7.3 Potentiometry. 6.4 6.6 6.8 6.9 6.9 6.9 USP<791> Eur.Ph 2.2.3;Eur.Ph 2.9.17 Coloration ≤Y6 Eur.Ph 2.2.2 <Y6 <Y5 <Y5 <Y5 <Y5 <Y5Particulate matter ≥10 μm: Light obscuration 2331 1083 229 148 N.R. 394≤6000 p/vial particle count ≥25 μm: USP<788> 43 2 3 2 N.R 2 ≤600 p/vialPh.Eur.2.9.19 Identification Ibuprofen Same retention USP<621> CompliesComplies Complies Complies Complies Complies Acetaminophen time asstandard Ph.Eur.2.2.29 Complies Complies Complies Complies CompliesComplies Cysteine Compiles Complies Complies Complies Complies CompliesAcetaminophen 95.0-105.0% Eur.Ph 2.2.29; 0049 102.0% 100.4% 101.9%100.7% 101.4% 99.9% content (HPLC) Ibuprofen content 95.0-105.0% Liquidchromatography 98.0% 99.7% 99.6% 98.7% 98.0% 100.2% (HPLC) USP<621> Inhouse-Ph.Eur.2.2.29 Cysteine 80-105% Liquid chromatography   84%   86%  84% 78.0% 77.2%  80.6% hydrochloride at release USP<621> monohydrateMin 40% In house-Ph.Eur.2.2.29 (HPLC) at s.h. Impurities AcetaminophenImpurity K ≤0.05% Eur.Ph 2.2.29; 0049 0.020 0.021 0.020 0.025 0.0280.030 (4-aminophenol) Impurity F ≤0.05% 0.000 0.000 0.000 0.000 0.0000.000 (4-nitrophenol) Any other impurity ≤0.10% 0.017 0.013 0.019 0.0100.017 0.011 Total impurities  ≤0.2% 0.037 0.035 0.039 0.035 0.045 0.041Impurities Ibuprofen Impurity A  ≤0.1% Eur.Ph 2.2.29 0.0 0.0 0.0 0.0 0.00.0 Impurity B  ≤0.2% 0.0 0.0 0.0 0.0 0.0 0.0 Any other impurity ≤0.10%0.00 0.00 0.00 0.00 0.00 0.00 Total impurities  ≤0.2% 0.0 0.0 0.0 0.00.0 0.0

What is claimed is:
 1. An aqueous composition, comprising ibuprofen andparacetamol, wherein the pH of said composition is 6.3 to 7.3, andwherein the composition is in a form suitable for intravenous injectionor infusion.
 2. The composition according to claim 1, comprising 2.8 to3.2 mg ibuprofen and 9.8 to 10.2 mg paracetamol expressed per ml of saidcomposition.
 3. The composition according to claim 1, further comprisingan isotonic agent.
 4. The composition according to claim 1, wherein saidcomposition has a storage stability of at least 6 months.
 5. Thecomposition according to claim 1, wherein said composition has adissolved oxygen content below 2 ppm.
 6. The composition according toclaim 2, comprising 3 mg ibuprofen and 10 mg paracetamol expressed perml of said composition.
 7. The composition according to claim 3, whereinthe isotonic agent is mannitol.
 8. The composition according to claim 4,wherein the composition has a storage stability of at least 12 months.